Les biothérapies immunomodulatrices du futur : quelles perspectives ?

Loo, 2008, Antibody engineering principles and applications, Cancer J, 14, 149, 10.1097/PPO.0b013e318173a5d5 Stohl, 2006, B cell depletion therapy in systemic rheumatic diseases: Different strokes for different folks?, Clin Immunol, 121, 1, 10.1016/j.clim.2006.03.010 Cartron, 2004, From the bench to the bedside: Ways to improve rituximab efficacy, Blood, 104, 2635, 10.1182/blood-2004-03-1110 Taylor, 2008, Immunotherapeutic mechanisms of anti-cd20 monoclonal antibodies, Curr Opin Immunol, 20, 444, 10.1016/j.coi.2008.05.011 Edwards, 2001, Sustained improvement in rheumatoid arthritis following a protocol designed to deplete b lymphocytes, Rheumatology (Oxford), 40, 205, 10.1093/rheumatology/40.2.205 Kavanaugh, 2008, Assessment of rituximab's immunomodulatory synovial effects (arise trial). 1:: Clinical and synovial biomarker results, Ann Rheum Dis, 67, 402, 10.1136/ard.2007.074229 Gunnarsson, 2007, Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis, Arthritis Rheum, 56, 1263, 10.1002/art.22505 Illei, 2007, Long-term effects of combination treatment with fludarabine and low-dose pulse cyclophosphamide in patients with lupus nephritis, Rheumatology (Oxford), 46, 952, 10.1093/rheumatology/kem001 Vigna-Perez, 2006, Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: A pilot study, Arthritis Res Ther, 8, R83, 10.1186/ar1954 Tokunaga, 2007, Efficacy of rituximab (anti-cd20) for refractory systemic lupus erythematosus involving the central nervous system, Ann Rheum Dis, 66, 470, 10.1136/ard.2006.057885 Amoura, 2008, Lupus systémique: les traitements du futur, Rev Med Interne, 29, 718, 10.1016/j.revmed.2008.02.013 Smith, 2006, Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment, Arthritis Rheum, 54, 2970, 10.1002/art.22046 Devauchelle-Pensec, 2007, Improvement of sjogren's syndrome after two infusions of rituximab (anti-cd20), Arthritis Rheum, 57, 310, 10.1002/art.22536 Chung, 2007, A pilot trial of rituximab in the treatment of patients with dermatomyositis, Arch Dermatol, 143, 763, 10.1001/archderm.143.6.763 Levine, 2005, Rituximab in the treatment of dermatomyositis:: An open-label pilot study, Arthritis Rheum, 52, 601, 10.1002/art.20849 Mok, 2007, Rituximab for refractory polymyositis: An open-label prospective study, J Rheumatol, 34, 1864 Keogh, 2005, Induction of remission by b lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis, Arthritis Rheum, 52, 262, 10.1002/art.20718 Keogh, 2006, Rituximab for refractory wegener's granulomatosis: report of a prospective, open-label pilot trial, Am J Respir Crit Care Med, 173, 180, 10.1164/rccm.200507-1144OC Stasi, 2006, Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab, Rheumatology (Oxford), 45, 1432, 10.1093/rheumatology/kel098 Saadoun, 2008, Rituximab combined with peg-interferon-ribavirin in refractory hepatitis c virus-associated cryoglobulinaemia vasculitis, Ann Rheum Dis, 67, 1431, 10.1136/ard.2007.081653 Joly, 2007, A single cycle of rituximab for the treatment of severe pemphigus, N Engl J Med, 357, 545, 10.1056/NEJMoa067752 Coiffier, 2008, Safety and efficacy of ofatumumab, a fully human monoclonal anti-cd20 antibody, in patients with relapsed or refractory b-cell chronic lymphocytic leukemia: A phase 1-2 study, Blood, 111, 1094, 10.1182/blood-2007-09-111781 Hagenbeek, 2008, First clinical use of ofatumumab, a novel fully human anti-cd20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial, Blood, 111, 5486, 10.1182/blood-2007-10-117671 Otipoby, 1996, Cd22 regulates thymus-independent responses and the lifespan of b cells, Nature, 384, 634, 10.1038/384634a0 Jacobi, 2008, Differential effects of epratuzumab on peripheral blood b cells of patients with systemic lupus erythematosus versus normal controls, Ann Rheum Dis, 67, 450, 10.1136/ard.2007.075762 Dorner, 2008, Correction: Initial clinical trial of epratuzumab (humanized anti-cd22 antibody) for immunotherapy of systemic lupus erythematosus, Arthritis Res Ther, 10, 406, 10.1186/ar2499 Steinfeld, 2006, Epratuzumab (humanised anti-cd22 antibody) in primary sjogren's syndrome: An open-label phase i/ii study, Arthritis Res Ther, 8, R129, 10.1186/ar2018 Zhang, 2001, Cutting edge:: A role for b lymphocyte stimulator in systemic lupus erythematosus, J Immunol, 166, 6, 10.4049/jimmunol.166.1.6 Cheema, 2001, Elevated serum b lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases, Arthritis Rheum, 44, 1313, 10.1002/1529-0131(200106)44:6<1313::AID-ART223>3.0.CO;2-S Groom, 2002, Association of baff/blys overexpression and altered b cell differentiation with sjogren's syndrome, J Clin Invest, 109, 59, 10.1172/JCI0214121 Tak, 2008, Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study, Arthritis Rheum, 58, 61, 10.1002/art.23178 Dall’Era, 2007, Reduced b lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase ib, double-blind, placebo-controlled, dose-escalating trial, Arthritis Rheum, 56, 4142, 10.1002/art.23047 Bingham, 2008, Emerging therapeutics for rheumatoid arthritis, Bull NYU Hosp Jt Dis, 66, 210 Devi, 1998, Peripheral blood lymphocytes in sle--hyperexpression of cd154 on t and b lymphocytes and increased number of double negative t cells, J Autoimmun, 11, 471, 10.1006/jaut.1998.0213 Early, 1996, Anti-cd40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of new zealand black x new zealand white mice. Response correlates with the absence of an anti-antibody response, J Immunol, 157, 3159, 10.4049/jimmunol.157.7.3159 Kalled, 1998, Anti-cd40 ligand antibody treatment of snf1 mice with established nephritis: Preservation of kidney function, J Immunol, 160, 2158, 10.4049/jimmunol.160.5.2158 Yellin, 1997, Immunohistologic analysis of renal cd40 and cd40l expression in lupus nephritis and other glomerulonephritides, Arthritis Rheum, 40, 124, 10.1002/art.1780400117 Boumpas, 2003, A short course of bg9588 (anti-cd40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis, Arthritis Rheum, 48, 719, 10.1002/art.10856 Kalunian, 2002, Treatment of systemic lupus erythematosus by inhibition of t cell costimulation with anti-cd154 : a randomized, double-blind, placebo-controlled trial, Arthritis Rheum, 46, 3251, 10.1002/art.10681 Kawai, 2000, Thromboembolic complications after treatment with monoclonal antibody against cd40 ligand, Nat Med, 6, 114, 10.1038/72162 Kremer, 2003, Treatment of rheumatoid arthritis by selective inhibition of t-cell activation with fusion protein ctla4ig, N Engl J Med, 349, 1907, 10.1056/NEJMoa035075 Weinblatt, 2006, Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs : a one-year randomized, placebo-controlled study, Arthritis Rheum, 54, 2807, 10.1002/art.22070 Ruperto, 2008, Abatacept in children with juvenile idiopathic arthritis: A randomised, double-blind, placebo-controlled withdrawal trial, Lancet, 372, 383, 10.1016/S0140-6736(08)60998-8 Keymeulen, 2005, Insulin needs after cd3-antibody therapy in new-onset type 1 diabetes, N Engl J Med, 352, 2598, 10.1056/NEJMoa043980 Bisikirska, 2005, Tcr stimulation with modified anti-cd3 mab expands cd8+ t cell population and induces cd8+cd25+ tregs, J Clin Invest, 115, 2904, 10.1172/JCI23961 Skov, 2003, Humax-cd4 : a fully human monoclonal anti-cd4 antibody for the treatment of psoriasis vulgaris, Arch Dermatol, 139, 1433, 10.1001/archderm.139.11.1433 Lundin, 2002, Phase ii trial of subcutaneous anti-cd52 monoclonal antibody alemtuzumab (campath-1h) as first-line treatment for patients with b-cell chronic lymphocytic leukemia (b-cll), Blood, 100, 768, 10.1182/blood-2002-01-0159 Walsh, 2008, Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (campath-1h), Ann Rheum Dis, 67, 1322, 10.1136/ard.2007.081661 Coles, 2008, Alemtuzumab vs. Interferon beta-1a in early multiple sclerosis, N Engl J Med, 359, 1786, 10.1056/NEJMoa0802670 Lorenzi, 2008, Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia : twelve-year outcomes, Arthritis Rheum, 58, 370, 10.1002/art.23122 Choy, 2002, Efficacy of a novel pegylated humanized anti-tnf fragment (cdp870) in patients with rheumatoid arthritis : a phase ii double-blinded, randomized, dose-escalating trial, Rheumatology (Oxford), 41, 1133, 10.1093/rheumatology/41.10.1133 Sandborn, 2007, Certolizumab pegol for the treatment of crohn's disease, N Engl J Med, 357, 228, 10.1056/NEJMoa067594 Schreiber, 2007, Maintenance therapy with certolizumab pegol for crohn's disease, N Engl J Med, 357, 239, 10.1056/NEJMoa062897 Kay, 2008, Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study, Arthritis Rheum, 58, 964, 10.1002/art.23383 Cohen, 2002, Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate:: Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial, Arthritis Rheum, 46, 614, 10.1002/art.10141 Cohen, 2004, A multicentre, double blind, randomised, placebo controlled trial of anakinra (kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate, Ann Rheum Dis, 63, 1062, 10.1136/ard.2003.016014 Gattorno, 2008, The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis, Arthritis Rheum, 58, 1505, 10.1002/art.23437 Lequerre, 2008, Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset still disease: Preliminary experience in france, Ann Rheum Dis, 67, 302, 10.1136/ard.2007.076034 Pascual, 2005, Role of interleukin-1 (il-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to il-1 blockade, J Exp Med, 201, 1479, 10.1084/jem.20050473 de Koning, 2006, Beneficial response to anakinra and thalidomide in schnitzler's syndrome, Ann Rheum Dis, 65, 542, 10.1136/ard.2005.045245 Hoffman, 2004, Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist, Lancet, 364, 1779, 10.1016/S0140-6736(04)17401-1 Yamazaki, 2008, Anakinra improves sensory deafness in a japanese patient with muckle-wells syndrome, possibly by inhibiting the cryopyrin inflammasome, Arthritis Rheum, 58, 864, 10.1002/art.23261 Rothenberg, 2008, Treatment of patients with the hypereosinophilic syndrome with mepolizumab, N Engl J Med, 358, 1215, 10.1056/NEJMoa070812 Ito, 2005, Treatment of crohn's disease with anti-il-6 receptor antibody, J Gastroenterol, 40, 32, 10.1007/BF02990576 Smolen, 2008, Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (option study): A double-blind, placebo-controlled, randomised trial, Lancet, 371, 987, 10.1016/S0140-6736(08)60453-5 Nishimoto, 2008, Successful treatment of a patient with takayasu arteritis using a humanized anti-interleukin-6 receptor antibody, Arthritis Rheum, 58, 1197, 10.1002/art.23373 Nishimoto, 2000, Improvement in castleman's disease by humanized anti-interleukin-6 receptor antibody therapy, Blood, 95, 56, 10.1182/blood.V95.1.56 Schottelius, 1999, Interleukin-10 signaling blocks inhibitor of kappab kinase activity and nuclear factor kappab DNA binding, J Biol Chem, 274, 31868, 10.1074/jbc.274.45.31868 Llorente, 2003, The role of interleukin-10 in systemic lupus erythematosus, J Autoimmun, 20, 287, 10.1016/S0896-8411(03)00043-X Llorente, 2000, Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus, Arthritis Rheum, 43, 1790, 10.1002/1529-0131(200008)43:8<1790::AID-ANR15>3.0.CO;2-2 Brodsky, 2008, Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria, Blood, 111, 1840, 10.1182/blood-2007-06-094136 Springer, 1995, Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration, Annu Rev Physiol, 57, 827, 10.1146/annurev.ph.57.030195.004143 Polman, 2006, A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis, N Engl J Med, 354, 899, 10.1056/NEJMoa044397 Targan, 2007, Natalizumab for the treatment of active crohn's disease: Results of the encore trial, Gastroenterology, 132, 1672, 10.1053/j.gastro.2007.03.024 Zlotnik, 2000, Chemokines : a new classification system and their role in immunity, Immunity, 12, 121, 10.1016/S1074-7613(00)80165-X Zipp, 2006, Blockade of chemokine signaling in patients with multiple sclerosis, Neurology, 67, 1880, 10.1212/01.wnl.0000244420.68037.86 Vergunst, 2008, Modulation of ccr2 in rheumatoid arthritis: A double-blind, randomized, placebo-controlled clinical trial, Arthritis Rheum, 58, 1931, 10.1002/art.23591 Shahrara, 2005, Amelioration of rat adjuvant-induced arthritis by met-rantes, Arthritis Rheum, 52, 1907, 10.1002/art.21033 Lang, 2007, The role of the innate immune response in autoimmune disease, J Autoimmun, 29, 206, 10.1016/j.jaut.2007.07.018 Yousry, 2006, Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy, N Engl J Med, 354, 924, 10.1056/NEJMoa054693 Rat, 2004, Rheumatoid arthritis: Direct and indirect costs, Joint Bone Spine, 71, 518, 10.1016/j.jbspin.2004.01.003 Leonard, 2008, Durable complete responses from therapy with combined epratuzumab and rituximab: Final results from an international multicenter, phase 2 study in recurrent, indolent, non-hodgkin lymphoma, Cancer, 113, 2714, 10.1002/cncr.23890